BBIO
BridgeBio Pharma Inc
65.60$
-1.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 89.7% | 87.4% | 92.2% | 77.6% | 66.9% | 78.4% | 78.9% | 84.5% | 84.1% | 80.5% | 86.0% | 89.8% | |
| 77.1% | 68.8% | 56.0% | 68.9% | 40.1% | 74.1% | 61.3% | 69.4% | 64.4% | 60.9% | 64.2% | 55.7% | |
| 82.9% | 79.6% | 61.2% | 73.9% | 40.1% | 74.1% | 61.3% | 70.1% | 64.7% | 62.8% | 68.6% | 59.2% | |
| 0.8% | 0.3% | 27.7% | 0.1% | 0.1% | 0.5% | 13.1% | 7.1% | 11.7% | 14.9% | 15.0% | 20.9% | |
| 2.5% | 3.0% | – | -3.6% | – | 0.0% | 0.4% | 1.7% | 2.5% | 2.9% | 2.4% | 4.3% | |
| 4.1% | 4.8% | 3.0% | 3.2% | 3.7% | 2.6% | 3.2% | 2.7% | 2.9% | 3.0% | 2.0% | 2.2% | |
| 282.2% | 345.7% | 222.1% | 236.2% | 283.2% | 258.6% | 285.9% | 264.6% | 292.6% | 321.9% | 265.5% | 305.9% | |
| 16.2% | 26.3% | 16.7% | 16.9% | 20.9% | 16.8% | 17.3% | 16.3% | 21.7% | 30.8% | 59.5% | 73.2% | |
| 0.6% | 0.8% | 0.5% | 0.6% | 0.7% | 0.5% | 0.6% | 1.3% | 0.5% | 1.9% | 41.8% | 45.3% | |
| 0.7% | 2.0% | 0.6% | 2.3% | 2.0% | 1.0% | 3.1% | 2.4% | 1.9% | 3.9% | 2.1% | 2.2% | |
| 262.8% | 316.0% | 202.0% | 216.2% | 258.6% | 187.2% | 209.6% | 171.2% | 185.4% | 197.9% | 140.5% | 158.3% | |
| -184.4% | -247.9% | -123.6% | -137.6% | -185.0% | -159.7% | -187.0% | -165.5% | -193.6% | -221.9% | -165.5% | -206.6% | |
| -365.2% | -468.6% | -305.6% | -336.0% | -425.8% | -336.8% | -370.2% | -319.0% | -363.5% | -408.2% | -290.7% | -339.9% | |
| 24.9% | 31.9% | 21.0% | 23.6% | 28.3% | 20.6% | 21.6% | 17.6% | 19.1% | 21.1% | 14.2% | 16.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.